The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.


< Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors

> Methods and compositions for generating bioactive assemblies of increased complexity and uses

> Multidimensional segmentation based on adaptive bounding box and ellipsoid models

~ 00525